A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, Biological Activity, and Pharmacokinetics of Orally Administered CF102 in Subjects With Chronic Hepatitis C Genotype 1.

Trial Profile

A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, Biological Activity, and Pharmacokinetics of Orally Administered CF102 in Subjects With Chronic Hepatitis C Genotype 1.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Namodenoson (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 03 Jan 2012 Primary endpoint 'Pharmacokinetic-parameters' has been met (9132610).
    • 03 Jan 2012 Results published in a Can-Fite BioPharma media release.
    • 03 Jan 2012 Status changed from recruiting to completed based on a Can-Fite BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top